-+ 0.00%
-+ 0.00%
-+ 0.00%
NovaBridge’s Subsidiary Visara Doses First Patient In ASCEND Study, Randomized Phase 2b Trial To Evaluate VIS-101 In Patients With Wet Age-Related Macular Degeneration
Share
Listen to the news

Head-to-head trial designed to evaluate VIS-101’s potential for sustained disease control with extended treatment intervals

Phase 2a results showed approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose

ROCKVILLE, Md., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Visara, Inc. ("Visara"), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. ("NovaBridge") (NASDAQ:NBP), today announced that the first patient has been dosed in its ASCEND study, a randomized Phase 2b trial designed to evaluate the efficacy, safety and durability of VIS-101, including its potential to enable extended treatment intervals after monthly loading doses, in patients with wet age-related macular degeneration ("wet AMD"). The approximately 244-patient study is evaluating two doses of VIS-101 (6 mg and 9 mg) head-to-head against 2 mg aflibercept and is being conducted in China in partnership with Everest Medicines (HKEX 1952.HK).

VIS-101 is a tetravalent, dual vascular endothelial growth factor ("VEGF")-A and angiopoietin-2 ("ANG-2") inhibitor, purpose-designed to have best-in-class efficacy and durability. VIS-101 is in development for retinal vascular diseases, including wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). In the randomized, dose ranging Phase 2a study, VIS-101 demonstrated rapid, robust, and durable treatment responses in wet AMD, along with a favorable safety profile. Approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose, supporting VIS-101’s potential for best-in-class durability.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending